Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Merck & Co., Inc.    MRK

MERCK & CO., INC.

(MRK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Summary
  • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
Strengths
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
  • Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart
Sector Pharmaceuticals - NEC
1st jan.Capitalisation (M$)Investor Rating
MERCK & CO., INC.-1.00%204 882
JOHNSON & JOHNSON3.92%430 552
ROCHE HOLDING AG3.06%308 615
NOVARTIS AG2.73%220 726
PFIZER INC.-0.71%203 159
ABBVIE INC.3.46%195 720
ELI LILLY AND COMPANY22.09%186 883
NOVO NORDISK A/S4.18%168 128
AMGEN INC.10.26%147 580
BRISTOL-MYERS SQUIBB COMPAN..4.08%145 890
ASTRAZENECA PLC6.19%139 483
SANOFI3.51%124 582
GLAXOSMITHKLINE PLC2.85%94 107
JIANGSU HENGRUI MEDICINE CO..1.02%92 231
CHUGAI PHARMACEUTICAL CO., ..2.11%88 992
DAIICHI SANKYO COMPANY, LIM..1.27%66 704
More Results
Financials (USD)
Sales 2020 48 199 M - -
Net income 2020 12 145 M - -
Net Debt 2020 15 159 M - -
P/E ratio 2020 17,1x
Yield 2020 3,02%
Capitalization 205 B 205 B -
EV / Sales 2020 4,57x
EV / Sales 2021 4,20x
Nbr of Employees 71 000
Free-Float 70,7%
Upcoming event on MERCK & CO., INC.
Notations Surperformance©
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes